The 3D laser-assisted bioprinting technology, by which organic tissues can be reproduced, allows for a precise positioning of the skin cells in three-dimensional structures. Through this, cells are cultivated within BASF’s skin model Mimeskin, which is the closest equivalent to the original physiological tissue of human skin.
“We are extremely pleased about this collaboration," said Dr. Fabien Guillemot, founder and president of Poietis. "Having long-term expertise in solutions for the dermocosmetics market, BASF understands the benefits of 3D laser-assisted bioprinting compared to conventional cell culture technologies and other bioprinting methods. The partnership also emphasizes bioprinted tissue models as an alternative to animal testing in cosmetics and dermopharmacy.”
Poietis’ bioprinting technology refines BASF’s skin model Mimeskin due to its advanced printing resolution. The laser-assisted bioprinting technology will be used in a first step to allow for automated reproduction of Mimeskin, followed by more advanced models containing additional cell types.
“Compared to other bioprinting methods the laser-assisted technology provides higher resolution when it comes to the patterning of cells," explained Dr. Sebastien Cadau, responsible for tissue engineering development at BASF. "The partnership with Poietis allows BASF to secure its strategic advantage in better understanding the skin mechanisms which support the development and testing of advanced cosmetic bioactives for skin care applications.”
Poietis was founded in September 2014 following a 2-year project at the Aquitaine Regional Incubator and after winning the French National Competition for Creation of Innovative Technology Companies. Poietis benefits from the research work conducted at the National Institute for Health and Medical Research (INSERM) and the University of Bordeaux in developing and using innovative 3D laser-assisted bioprinting technology to design, develop and manufacture biological tissues. This innovative technology operates on the principles of 3D printing and proceeds by layer-by-layer assembly of the constituents of biological tissues according to predefined 3D digital design organizations. The exclusive use of this technology allows Poietis to produce more complex, robust and customizable tissues than the ones currently obtained by the conventional methods of cell culture and tissue engineering.